About us
Team
Investment strategy
Investment criteria
Investment process
Portfolio
News
Contact
home
|
espaņol
PORTFOLIO
|
Archive
TiGenix Reports Business & Financial Results for the First Quarter 2012.
15.05.12
Endosense reports strong momentum for contact-force sensing in catheter ablation at heart rhythm 2012.
14.05.12
TiGenix obtains manufacturing license for European production facility.
24.04.12
TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety hurdle.
17.04.12
TiGenix appoints Dr. Guido Schopen as vice president commercial operations.
10.04.12
AM-Pharma Announces Appointment of Industry Expert Guido Magni as Board Member.
16.03.12
TiGenix Reports Full Year 2011 Financial Results.
15.03.12
TiGenix announces changes in management responsibilities.
16.02.12
TiGenix rheumatoid arthritis Phase IIa study opens third and last cohort.
01.02.12
Endosense launches TactiCath 75 force-sensing catheter, announces new results of EFFICAS clinical study.
12.01.12
AM-Pharma Announces Appointment of Russell Greig as Chairman.
12.01.12
TiGenix Reports Positive Results of ChondroCelect. Compassionate Use Program.
09.01.12
TiGenix obtains € 2.9 Million FP7 grant to fund development of Cx611 in rheumatoid arthritis.
23.12.11
TiGenix receives green light to start Phase I with Cx621.
20.12.11
TiGenix to Present at 2011 Stem Cell Meeting on the Mesa.
23.11.11
TiGenix Reports Business & Financial Results for the Third Quarter 2011.
03.11.11
TiGenix rheumatoid arthritis Phase IIa study moves into randomized recruitment.
25.10.11
Sabirmedical appoints Dr. Wolfgang Reim as Chairman of the Board.
18.10.11
Cardoz announces the successful completion of enrollment in the AORTA trial investigating CRD007 in patients with Abdominal Aortic Aneurysm.
05.10.11
TiGenix to receive €5 Million financing facility for phase III fistula program in Crohn’s disease.
03.10.11
TiGenix announces the publication of positive ChondroCelect 5 year data in the American Journal of Sports Medicine.
19.09.11
Endosense names Jan Keltjens president and chief executive officer.
14.09.11
Tigenix financial update.
25.08.11
Endosense reports completion of first patient case utilizing contactforce visualization software, developed in cooperation with Siemens.
11.07.11
Cardoz announces the start of the international phase II dose-finding AORTA trial investigating a new oral drug treatment for Abdominal Aortic Aneurysm.
08.06.11
TiGenix announces the successful closing of the rights issue.
31.05.11
Tigenix business and Financial Update Q1 2011.
19.05.11
Oriol Solà-Morales joins Sabirmedical.
10.05.11
Endosense reinforces clinical leadership in contact-forece sensing.
9.05.11
Endosense and Biotronik mark 1,000th procedure performed with the Tacticath® force-sensing ablation catheter.
5.05.11
Rhythmia medical and Endosense announce joint development.
4.05.11
Endosense and Siemens Healthcare unveil prototype software visualizing contact-force data in 3-d anatomic heart model.
4.05.11
TiGenix announces proposed combination with Cellerix and capital increase through a public rights offering
01.03.11
Results on Phase IIa clinical trial of CELLERIX Cx601 product demonstrate good safety and efficacy profiles.
15.02.11
AMGEN to acquire BIOVEX, a privately held biotechnology company headquartered in Woburn, Mass.
25.01.11
Axis invests 1M€ in Sabirmedical.
10.01.11
Cellerix raises €27 million in a first closing.
11.11.09
Cellerix names board member Eduard E Holdener.
03.03.09
Cellerix raises 27 million in a first closing.
11.11.09
Cellerix names board member Eduard E Holdener.
03.03.09
Alfonso Camba appointed VP Manufacturing Operations of Cellerix.
11.11.08
Ontaril Closer to Market.
21.10.08
Joël Jean-Mairet to become Chairman of Cellerix.
13.10.08
Cellerix obtains a 10m debt facility with ETC Capital.
01.10.08
Cellerix grants Axcan rights to Cx401 in North America.
02.10.07
Ysios Capital Partners
|
Contact
|
Español
|
Design by amc
|
Ysios © 2010
